Foghorn Therapeutics Inc.
FHTX
Rank in Stocks
#18841
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company... Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
Share Price
$2.04
Last synced: 2026-11-09
Market Cap
$121.15M
Change (1 day)
9.09%
Change (1 year)
-54.05%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Foghorn Therapeutics Inc. (FHTX)
Category
Healthcare
EPS for Foghorn Therapeutics Inc. (FHTX)
EPS as of June 2026 TTM: $-0.99
According to Foghorn Therapeutics Inc.'s latest financial reports, its current EPS (TTM) is $-0.99. At the end of 2025 the company had an EPS of $-1.18, an increase over its 2024 EPS of $-1.58.
EPS history for Foghorn Therapeutics Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.99 | -16.10% |
| 2025 | $-1.18 | -25.32% |
| 2024 | $-1.58 | -32.48% |
| 2023 | $-2.34 | -10.69% |
| 2022 | $-2.62 | -5.76% |
| 2021 | $-2.78 | 46.32% |
| 2020 | $-1.90 | 35.71% |
| 2019 | $-1.40 | 4.48% |
| 2018 | $-1.34 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,681.82% |
US
|
|
| $-7.07 | 614.14% |
US
|
|
| $-5.29 | 434.34% |
AU
|
|
| $12.88 | -1,401.02% |
BE
|
|
| $21.56 | -2,277.78% |
NL
|
Questions about Foghorn Therapeutics Inc.'s earnings per share (EPS)
What is Foghorn Therapeutics Inc.'s earnings per share (EPS)?
Foghorn Therapeutics Inc.'s earnings per share (EPS) over the last twelve months is $-0.99, as of Jun 2026.
What was Foghorn Therapeutics Inc.'s earnings per share (EPS) in 2025?
In 2025, Foghorn Therapeutics Inc.'s earnings per share (EPS) was $-1.18, compared with $-1.58 in 2024.
How has Foghorn Therapeutics Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Foghorn Therapeutics Inc.'s earnings per share (EPS) was highest in 2025 ($-1.18) and lowest in 2021 ($-2.78).
How does Foghorn Therapeutics Inc.'s earnings per share (EPS) compare with similar companies?
Foghorn Therapeutics Inc.'s earnings per share (EPS) ($-0.99) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.